<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709096</url>
  </required_header>
  <id_info>
    <org_study_id>BPX-01-C02</org_study_id>
    <nct_id>NCT02709096</nct_id>
  </id_info>
  <brief_title>BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes</brief_title>
  <official_title>BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioPharmX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioPharmX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate
      the comparative reduction of Propionibacterium acnes in-vivo following once daily topical
      administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the comparative reduction of Propionibacterium
      acnes (P. acnes) in-vivo following once daily topical administration of BPX-01 Minocycline 1%
      Topical Gel or BPX-01 Vehicle control Gel.

      A secondary objective is to assess the tolerance of the treatment regimen versus a vehicle
      control. Safety laboratory data (chemistry and hematology) and plasma levels of minocycline
      are also of significant interest to the sponsor.

      This is a single center, randomized, double blind, two-cell, vehicle controlled P. acnes
      study. All subjects will be randomized 2:1 to 1% BPX-01 or vehicle control to be applied as a
      topical gel once daily for four (4) weeks.

      This is a six (6) week study with a four (4) week treatment period and a two (2) week post
      treatment follow up visit. The clinical endpoint is in-vivo quantification of P.acnes. The
      safety/tolerance endpoints are; observer reported: erythema, scaling-peeling, edema, and
      subject reported: tightness, burning-stinging, and itching. Plasma levels of minocycline and
      basic hematology and chemistry laboratory values will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes</measure>
    <time_frame>Cultures will be evaluated at Baseline, Week 1, Week 2, Week 4 and Week 6. Values reported at week 4 compared to baseline.</time_frame>
    <description>P. Acnes cultures will be collected using the modified Kligman Method at each study visit. After plating, the samples will be cultured for 7 days and then evaluated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>BPX-01, 1% Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPX-01, Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BPX-01, Vehicle Gel; applied once daily to the face for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPX-01, 1% Topical Gel</intervention_name>
    <description>topical gel, applied to the forehead, cheeks, nose and chin</description>
    <arm_group_label>BPX-01, 1% Topical Gel</arm_group_label>
    <other_name>BPX-01 Topical Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPX-01 Vehicle Gel</intervention_name>
    <description>topical gel, applied to the forehead, cheeks, nose and chin</description>
    <arm_group_label>BPX-01, Vehicle Gel</arm_group_label>
    <other_name>BPX-01 Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be a healthy, adult male and/or female volunteer 18 to 40 years of age with no past or
             present history of any significant disease based on PI discretion;

          2. If female, must be post-menopausal, surgically sterile, or using effective birth
             control methods with a negative urine pregnancy test at the Screening and Baseline
             visits (female subjects of childbearing potential only);

          3. Show a high degree of fluorescence of the face under a Wood's lamp at the screening
             visit.

          4. Be willing to refrain from using antimicrobial topical products for the duration of
             study participation;

          5. Be willing to return to the study center for all study visits;

          6. Be willing to follow all study instructions and adhere to study restrictions;

          7. Provide informed consent to the study procedures and restrictions

        Exclusion Criteria:

          1. Have a history of skin disease or presence of skin condition the PI believes would
             interfere with the study;

          2. Females who report that they are pregnant, planning a pregnancy or breastfeeding or
             those females who are of child bearing potential, that test positive with a urine
             pregnancy test;

          3. Have conditions or factors that the PI believes may affect the response of the skin or
             the interpretation of the results;

          4. Participated in any clinical study within the previous 30 days, be concurrently
             participating in other studies, or be involved in any aspect of test administration;

          5. Use of topical or systemic antibiotics or other products within the previous 4 weeks
             prior to baseline, that influence P. acnes counts;

          6. Are known to be allergic to any of the test product(s) or any components in the test
             product(s);

          7. Have a history of significant medical condition/disease that the PI believes may
             affect the response of the skin or the interpretation of the results;

          8. Has any other condition that, in the opinion of the Investigator or his designee,
             could interfere with the subject's ability to use the treatment as instructed, alter
             their treatment response, or affect their ability to complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Lessin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGL, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGL Skin Study Center</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <results_first_submitted>July 18, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2017</results_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BPX-01, 1% Topical Gel</title>
          <description>BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
BPX-01, 1% Topical Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
        </group>
        <group group_id="P2">
          <title>BPX-01, Vehicle Gel</title>
          <description>BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
BPX-01 Vehicle Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BPX-01, 1% Topical Gel</title>
          <description>BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
BPX-01, 1% Topical Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
        </group>
        <group group_id="B2">
          <title>BPX-01, Vehicle Gel</title>
          <description>BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
BPX-01 Vehicle Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="19" upper_limit="41"/>
                    <measurement group_id="B2" value="34" lower_limit="24" upper_limit="40"/>
                    <measurement group_id="B3" value="32" lower_limit="19" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes</title>
        <description>P. Acnes cultures will be collected using the modified Kligman Method at each study visit. After plating, the samples will be cultured for 7 days and then evaluated.</description>
        <time_frame>Cultures will be evaluated at Baseline, Week 1, Week 2, Week 4 and Week 6. Values reported at week 4 compared to baseline.</time_frame>
        <population>Per protocol population included all subjects with evaluable data and no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>BPX-01, 1% Topical Gel</title>
            <description>BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
BPX-01, 1% Topical Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
          </group>
          <group group_id="O2">
            <title>BPX-01, Vehicle Gel</title>
            <description>BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
BPX-01 Vehicle Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
          </group>
        </group_list>
        <measure>
          <title>Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes</title>
          <description>P. Acnes cultures will be collected using the modified Kligman Method at each study visit. After plating, the samples will be cultured for 7 days and then evaluated.</description>
          <population>Per protocol population included all subjects with evaluable data and no major protocol violations.</population>
          <units>log change in colony forming units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0376" spread="0.5479"/>
                    <measurement group_id="O2" value="-0.4614" spread="0.4042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BPX-01, 1% Topical Gel</title>
          <description>BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
BPX-01, 1% Topical Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
        </group>
        <group group_id="E2">
          <title>BPX-01, Vehicle Gel</title>
          <description>BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
BPX-01 Vehicle Gel: topical gel, applied to the forehead, cheeks, nose and chin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AnnaMarie Daniels</name_or_title>
      <organization>BioPharmX, Inc.</organization>
      <phone>310-701-2080</phone>
      <email>amdaniels@biopharmx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

